The U.K. drug regulator has told healthcare professionals to exercise caution when considering switching between long-acting attention deficit hyperactivity disorder therapies from companies including Johnson & Johnson, Novartis and Takeda. After wrapping up a phase 3 trial of its subcutaneous efgartigimod, argenx has submitted the data to the FDA to support a targeted approval in the treatment of generalized myasthenia gravis. Lipocine has rethought its strategy, focusing on the oral delivery of central nervous system in a pivot that leaves it looking for partners for potential treatments of conditions including nonalcoholic steatohepatitis and cirrhosis. | 